# Brazilian malaria vaccine clinical trials > Live situation record from CLSTR: https://clstr.news/situations/brazilian-malaria-vaccine-clinical-trials > Updated: 2026-10-15T17:51:00.000Z. Sources: 8. Developments: 2. Brazil’s National Health Surveillance Agency (Anvisa) has authorized Phase I human clinical trials for a new vaccine targeting the Plasmodium vivax parasite. Developed by researchers from the Federal University of Minas Gerais (UFMG), the University of São Paulo (USP), the Vaccine Technology Center (CTVacinas), and the pharmaceutical company Cristália, the vaccine—identified as Vivaxin—uses recombinant chimeric protein technology. Unlike existing malaria vaccines that target the Plasmodium falciparum parasite, this vaccine is designed for the strain predominant in the Americas and Asia. The initial study will involve 48 healthy volunteers aged 18 to 59 to evaluate safety, tolerability, and immune response over a 12-month period. While pre-clinical studies in mice and primates showed 100% protection, the vaccine is not yet available for public use. If Phase I is successful, subsequent research phases will involve approximately 300 volunteers, primarily located in the Amazon region, where over 95% of Brazil’s malaria cases occur. The Ministry of Health has projected an investment of R$ 12 million to support the clinical trials through Phases I, II, and III. ## Timeline ### 2026-10-15: Anvisa authorizes human trials for first Brazilian malaria vivax vaccine Anvisa has authorized Phase 1 human trials for Vivaxin, a pioneering Brazilian vaccine targeting Plasmodium vivax malaria, the most common species in Brazil and the Americas. 2 sources. https://clstr.news/cluster/anvisa-authorizes-human-trials-for-first-brazilian-malaria-vivax-vaccine ### 2026-10-12: Anvisa authorizes human trials for Brazilian malaria vaccine Anvisa has authorized human trials for a Brazilian-developed vaccine targeting the Plasmodium vivax malaria parasite, focusing on safety and immune response in an initial group of 48 volunteers. 7 sources. https://clstr.news/cluster/anvisa-authorizes-human-trials-for-brazilian-malaria-vaccine-2 --- Cite as: Brazilian malaria vaccine clinical trials. CLSTR, https://clstr.news/situations/brazilian-malaria-vaccine-clinical-trials